Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Tazverik (tazemetostat)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Eisai, Hutchmed, Ipsen

Drug class:

EZH2 inhibitor

Related drugs:

EZH2 mutation	Follicular Lymphoma	EZH2 mutation	Follicular Lymphoma	tazemetostat Sensitive: A1 - Approval tazemetostat Sensitive : A1	tazemetostat Sensitive: A1 - Approval tazemetostat Sensitive : A1
No biomarker	Soft Tissue Sarcoma	No biomarker	Soft Tissue Sarcoma	tazemetostat Sensitive: A1 - Approval tazemetostat Sensitive : A1	tazemetostat Sensitive: A1 - Approval tazemetostat Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	tazemetostat Sensitive: A2 - Guideline tazemetostat Sensitive : A2	tazemetostat Sensitive: A2 - Guideline tazemetostat Sensitive : A2
EZH2 mutation	Diffuse Large B Cell Lymphoma	EZH2 mutation	Diffuse Large B Cell Lymphoma	tazemetostat Sensitive: C1 - Off-label tazemetostat Sensitive : C1	tazemetostat Sensitive: C1 - Off-label tazemetostat Sensitive : C1
SMARCB1 negative	Chordoma	SMARCB1 negative	Chordoma	tazemetostat Sensitive: C2 – Inclusion Criteria tazemetostat Sensitive : C2	tazemetostat Sensitive: C2 – Inclusion Criteria tazemetostat Sensitive : C2
BAP1 mutation	Mesothelioma	BAP1 mutation	Mesothelioma	tazemetostat Sensitive: C2 – Inclusion Criteria tazemetostat Sensitive : C2	tazemetostat Sensitive: C2 – Inclusion Criteria tazemetostat Sensitive : C2
SMARCB1 negative	Spindle Cell Sarcoma	SMARCB1 negative	Spindle Cell Sarcoma	tazemetostat Sensitive: C3 – Early Trials tazemetostat Sensitive : C3	tazemetostat Sensitive: C3 – Early Trials tazemetostat Sensitive : C3
SMARCB1 deletion	Soft Tissue Sarcoma	SMARCB1 deletion	Soft Tissue Sarcoma	tazemetostat Sensitive: C3 – Early Trials tazemetostat Sensitive : C3	tazemetostat Sensitive: C3 – Early Trials tazemetostat Sensitive : C3
SMARCB1 mutation	Sarcoma	SMARCB1 mutation	Sarcoma	tazemetostat Sensitive: C3 – Early Trials tazemetostat Sensitive : C3	tazemetostat Sensitive: C3 – Early Trials tazemetostat Sensitive : C3
SMARCB1 A240fsX28	Sarcoma	SMARCB1 A240fsX28	Sarcoma	tazemetostat Sensitive: C3 – Early Trials tazemetostat Sensitive : C3	tazemetostat Sensitive: C3 – Early Trials tazemetostat Sensitive : C3
BCL2 fusion + EZH2 mutation	Diffuse Large B Cell Lymphoma	BCL2 fusion + EZH2 mutation	Diffuse Large B Cell Lymphoma	venetoclax + tazemetostat Sensitive: D – Preclinical venetoclax + tazemetostat Sensitive : D	venetoclax + tazemetostat Sensitive: D – Preclinical venetoclax + tazemetostat Sensitive : D
EZH2 Y646F	Non-Hodgkin’s Lymphoma	EZH2 Y646F	Non-Hodgkin’s Lymphoma	tazemetostat Sensitive: D – Preclinical tazemetostat Sensitive : D	tazemetostat Sensitive: D – Preclinical tazemetostat Sensitive : D
EZH2 A682G	Non-Hodgkin’s Lymphoma	EZH2 A682G	Non-Hodgkin’s Lymphoma	tazemetostat Sensitive: D – Preclinical tazemetostat Sensitive : D	tazemetostat Sensitive: D – Preclinical tazemetostat Sensitive : D
PBRM1 mutation	Chordoma	PBRM1 mutation	Chordoma	tazemetostat Sensitive: D – Preclinical tazemetostat Sensitive : D	tazemetostat Sensitive: D – Preclinical tazemetostat Sensitive : D
EZH2 W113C	Lymphoma	EZH2 W113C	Lymphoma	tazemetostat Resistant: D – Preclinical tazemetostat Resistant : D	tazemetostat Resistant: D – Preclinical tazemetostat Resistant : D
SOX17 overexpression	Endometrial Cancer	SOX17 overexpression	Endometrial Cancer	tazemetostat + AC1Q3QWB Sensitive: D – Preclinical tazemetostat + AC1Q3QWB Sensitive : D	tazemetostat + AC1Q3QWB Sensitive: D – Preclinical tazemetostat + AC1Q3QWB Sensitive : D
CDKN1A overexpression	Endometrial Cancer	CDKN1A overexpression	Endometrial Cancer	tazemetostat + AC1Q3QWB Sensitive: D – Preclinical tazemetostat + AC1Q3QWB Sensitive : D	tazemetostat + AC1Q3QWB Sensitive: D – Preclinical tazemetostat + AC1Q3QWB Sensitive : D